Neoadjuvant Nivolumab in Glioblastoma

Phase 2 Completed 29 enrolled Clinica Universidad de Navarra, Universidad de Navarra

NaSingle-groupOpen-labelTreatment

Summary

Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.

Timeline

Start: 2015-06
Primary completion: 2017-03
Completion: 2017-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	3 mg	Intravenous

Neoadjuvant Nivolumab in Glioblastoma

Summary

Timeline

Drugs

Indications